These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 579100)

  • 21. Pharmacology of amezinium, a novel antihypotensive drug. VI. Effect on central nervous functions.
    Teschendorf HJ; Kretzschmar R; Kreiskott H; Weifenbach H
    Arzneimittelforschung; 1981; 31(9a):1580-8. PubMed ID: 7197973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effects of ritodrine hydrochloride on motor nervous system and central nervous system].
    Ikeda S; Tsukamoto T
    Nihon Yakurigaku Zasshi; 1984 Sep; 84(3):311-26. PubMed ID: 6500405
    [TBL] [Abstract][Full Text] [Related]  

  • 23. L-6-ketopiperidine-2-carbonyl-L-leucyl-L-proline amide as a novel thyrotropin releasing hormone analogue with improving effects on impaired central nervous systems functions.
    Oka M; Ochi Y; Furukawa K; Ito T; Miura Y; Karasawa T; Kadokawa T
    Arzneimittelforschung; 1989 Mar; 39(3):297-303. PubMed ID: 2547386
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological actions of the antihypertensive agent N-amidino-2-(2,6-dichlorophenyl)acetamide hydrochloride (BS 100-141).
    Scholtysik G; Lauener H; Eichenberger E; Bürki H; Salzmann R; Müller-Schweinitzer E; Waite R
    Arzneimittelforschung; 1975 Oct; 25(10):1483-91. PubMed ID: 1243025
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antihypertensive and general pharmacological properties of budralazine.
    Chiba T; Shibamura S; Tanaka M; Yamasaki T; Hashimoto H; Kurebayashi Y; Kasai Y; Ryokawa Y; Tamura K; Hirohashi M; Akashi A
    Arzneimittelforschung; 1981; 31(7):1080-7. PubMed ID: 7023495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Circulatory changes with urapidil (Ebrantil) in general and regional anesthesia. Studies with normo- and hypertensive patients].
    Lehmann KA; Heimig T
    Anaesthesist; 1985 Sep; 34(9):435-45. PubMed ID: 4083465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. General pharmacological profile of the novel cholecystokinin-A antagonist loxiglumide.
    Saito T; Ukai K; Masuda T; Nakagawa T; Kimura K; Fujii M; Wakatsuki K; Saeki M; Kasai H
    Arzneimittelforschung; 1997 Dec; 47(12):1375-82. PubMed ID: 9450167
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacology of the new H1-receptor antagonist setastine hydrochloride.
    Porszász J; Varga F; Porszász KG; Szolscányi J; Barthó L; Petöcz L; Kápolnai L
    Arzneimittelforschung; 1990 Dec; 40(12):1340-5. PubMed ID: 1982751
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Cardiovascular effects of urapidil].
    Bousquet P; Decker N; Feldman J; Schwartz J
    J Pharmacol; 1983; 14(4):465-72. PubMed ID: 6672466
    [TBL] [Abstract][Full Text] [Related]  

  • 30. General pharmacology of the anxiolytic compound metaclazepam in comparison to other benzodiazepines.
    Buschmann G; Kühl UG; Rohte O
    Arzneimittelforschung; 1985; 35(11):1643-55. PubMed ID: 2868732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [General pharmacologic studies on the analgesic flupirtine].
    Jakovlev V; Achterrath-Tuckermann U; von Schlichtegroll A; Stroman F; Thiemer K
    Arzneimittelforschung; 1985; 35(1):44-55. PubMed ID: 4039152
    [TBL] [Abstract][Full Text] [Related]  

  • 32. General pharmacology of the new non-xanthine adenosine A1 receptor antagonist (+)-(R)-[(E)-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)acryloyl]-2- piperidine ethanol.
    Terai T; Kusunoki T; Kita Y; Yoshida K; Akahane A; Shiokawa Y; Kohno Y; Horiai H; Mori J; Mine Y; Kohsaka M
    Arzneimittelforschung; 1996 Feb; 46(2):185-91. PubMed ID: 8720311
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pharmacological investigations with the combination sulfamoxole/trimethoprim, a new broadspectrum chemotherapeutic agent (author's transl)].
    Gries J; Kretzschmar R; Kuhne J; Neumann W; Osterloh G; Scherschlicht R; Worstmann W
    Arzneimittelforschung; 1976; 26(42):623-33. PubMed ID: 947323
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Screening pharmacological studies of four dihydroisoquinoline derivatives.
    Stoychev T; Koleva M; Orahovats A; Trifonov L
    Acta Physiol Pharmacol Bulg; 1979; 5(3):82-90. PubMed ID: 539451
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacological studies of new indole alkaloids, rugulovasine A and B hydrochloride.
    Nagaoka A; Kikuchi K; Nagawa Y
    Arzneimittelforschung; 1972 Jan; 22(1):137-42. PubMed ID: 5066988
    [No Abstract]   [Full Text] [Related]  

  • 36. Pharmacological studies on 1-methyl-7-nitro-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one (S-1530).
    Sakai S; Kitagawa S; Yamamoto H
    Arzneimittelforschung; 1972 Mar; 22(3):534-9. PubMed ID: 5067925
    [No Abstract]   [Full Text] [Related]  

  • 37. Synthesis and pharmacological activity of befuraline (N-benzo[b]furan-2-ylcarbonyl-N'-benzylpiperazine), a new antidepressant compound.
    Boksay IJ; Popendiker K; Weber RO; Söder A
    Arzneimittelforschung; 1979; 29(2):193-204. PubMed ID: 582130
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Contribution on the pharmacology of gamma-butyrolactone].
    Hampel H; Hapke HJ
    Arch Int Pharmacodyn Ther; 1968 Feb; 171(2):306-22. PubMed ID: 5685835
    [No Abstract]   [Full Text] [Related]  

  • 39. Pharmacological studies of mabuterol, a new selective beta 2-stimulant. III: Effects on the central nervous system, striated muscle and carbohydrate and lipid metabolism.
    Osada E; Sakaya S; Sanai K; Seri K
    Arzneimittelforschung; 1984; 34(11A):1652-8. PubMed ID: 6152158
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Suppression of reflex tachycardia by central administration of the alpha-1 adrenoceptor antagonists urapidil and prazosin in anesthetized dogs.
    Shebuski RJ; Zimmerman BG
    J Pharmacol Exp Ther; 1985 Aug; 234(2):456-62. PubMed ID: 2862276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.